| 今开：1.21 | 昨收：1.21 |
| 最高：1.2318 | 最低：1.18 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：4.5787602E7 |
Bioxcel Therapeutics(BTAI)04-22 19:15
$Bioxcel Therapeutics(BTAI)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001104659-24-049691 Act: 34 Size: 17 MB 网页链接查看全文
Bioxcel Therapeutics(BTAI)06-12 07:05
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-070514 Size: 5 KB 网页链接查看全文
Bioxcel Therapeutics(BTAI)06-12 18:05
$Bioxcel Therapeutics(BTAI)$ 8-K Current report, items 5.03, 5.07, and 9.01 Accession Number: 0001104659-24-070503 Act: 34 Size: 234 KB 网页链接查看全文
Bioxcel Therapeutics(BTAI)06-18 01:55
$Bioxcel Therapeutics(BTAI)$ 144 Report of proposed sale of securities Accession Number: 0001971857-24-000412 Act: 33 Size: 5 KB 网页链接查看全文
Bioxcel Therapeutics(BTAI)06-18 01:25
$Bioxcel Therapeutics(BTAI)$ 144 Report of proposed sale of securities Accession Number: 0001971857-24-000411 Act: 33 Size: 5 KB 网页链接查看全文
Bioxcel Therapeutics(BTAI)06-25 19:15
$Bioxcel Therapeutics(BTAI)$ 8-K Current report, item 8.01 Accession Number: 0001104659-24-074545 Act: 34 Size: 194 KB 网页链接查看全文
Bioxcel Therapeutics(BTAI)06-19 17:25
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-073002 Size: 12 KB 网页链接查看全文
Bioxcel Therapeutics(BTAI)06-19 17:25
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-073003 Size: 9 KB 网页链接查看全文
Bioxcel Therapeutics(BTAI)06-19 17:25
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-072999 Size: 15 KB 网页链接查看全文
Bioxcel Therapeutics(BTAI)06-07 08:35
$Bioxcel Therapeutics(BTAI)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001104659-24-069194 Act: 34 Size: 72 KB 网页链接查看全文
chuminhua2023-10-26 11:00
10/25，BioXcel Therapeutics $Bioxcel Therapeutics(BTAI)$ 宣布，独立第三方审计确认其实验性阿尔茨海默病治疗药物 BXCL501 的 III 期试验不存在数据完整性问题，周三该公司股价在盘前交易中上涨了 40%。
6 月，BioXcel 报告称，BXCL501 的 III 期 TRANQUILITY II 试验已达到其主要终点。BXC...查看全文
chuminhua2023-08-15 10:57
8/14，BioXcel Therapeutics $Bioxcel Therapeutics(BTAI)$ 仍因近期一项关键研究的数据完整性问题而困扰，宣布作为战略改革的一部分，将把员工人数从约 190 人减少到 80 人。 该公司股价周一下跌 45%，该公司表示，未来计划将重点放在“高潜力的激动人心的市场机会”上。
首席执行官 Vimal Me...查看全文
SeekingBiotech2023-08-14 21:34
BTAI reported its second quarter 2023 financials and announced plans to reduce nearly 60% of its workforce as part of a reprioritization of its business operation
$Bioxcel Therapeutics(BTAI)$
右美托咪定改良新药等。查看全文
不入流资讯2023-08-14 21:04
$Bioxcel Therapeutics(BTAI)$ BioXcel Therapeutics to cut workforce 58%, stock falls 30%查看全文
冷小二2023-08-11 10:24
$Bioxcel Therapeutics(BTAI)$ 还有救吗？目前似乎也没说一定是造假吧？According to Reuters, the company said one trial site's lead investigator was found to have fabricated emails related to the timing of a serious side effect with the company's vendor that was responsib...查看全文
美股律师郝俊波2023-07-08 12:02
$Bioxcel Therapeutics(BTAI)$ 【BioXcel Therapeutics(BTAI)最新证券集体诉讼】
BioXcel Therapeutics Inc(BTAI)因证券欺诈案已经于近日被投资者集体诉讼至法院。在目前的诉讼中投资者指控该公司及部分高管在本案诉讼期间进行虚假陈述，违反证券法令投资者受损。投资者向法院申请判令被告赔...查看全文
产业链观察2023-06-29 21:36
#药闻简讯# $Bioxcel Therapeutics(BTAI)$ 宣布BXCL501急性治疗阿尔茨海默病相关惊厥的TRANQUILITY II 3期试验取得积极的顶线结果。
试验达到了60微克剂量的主要终点，与安慰剂相比，BXCL501在2小时内的PEC评分从基线下降了39%，具有统计学意义（P=0.0112）。
实验达到了关键的次要终点，...查看全文
生物制药公司BioXcel Therapeutics(BTAI.US)盘前跌4.11%，报4.2美元。瑞穗将BioXcel Therapeutics的股票评级从“买入”下调至“中性”，并将其目标价从40美元下调至4美元，此前该公司在第二季度财报中宣布了重... 网页链接
格隆汇3月10日丨BioXcel Therapeutics(BTAI.US)现跌5.53%，报17.845美元，总市值5亿美元。BioXcel Therapeutics公布，2021年第四季度稀释后每股净亏损0.93美元，高于去年同期的每股亏损0.87美元，Capital IQ调查的分析师预计每股亏损1.14美元。 网页链接
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-21-081587 Size: 14 KB 网页链接
$Bioxcel Therapeutics(BTAI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-21-081589 Size: 14 KB 网页链接
$Bioxcel Therapeutics(BTAI)$ 8-K Current report, items 5.03, 5.07, and 9.01 Accession Number: 0001104659-21-080770 Act: 34 Size: 40 KB 网页链接
$Bioxcel Therapeutics(BTAI)$ 8-K Current report, items 1.01 and 9.01 Accession Number: 0001104659-21-063935 Act: 34 Size: 309 KB 网页链接
$Bioxcel Therapeutics(BTAI)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001047469-21-001109 Act: 33 Size: 285 KB 网页链接
$Bioxcel Therapeutics(BTAI)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-21-006663 Act: 34 Size: 3 MB 网页链接
$Bioxcel Therapeutics(BTAI)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-21-063384 Act: 34 Size: 72 KB 网页链接
$Bioxcel Therapeutics(BTAI)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001104659-21-055612 Act: 34 Size: 429 KB 网页链接
$Bioxcel Therapeutics(BTAI)$ DEF 14A Other definitive proxy statements Accession Number: 0001104659-21-055605 Act: 34 Size: 1 MB 网页链接
$Bioxcel Therapeutics(BTAI)$ PRE 14A Other preliminary proxy statements Accession Number: 0001104659-21-050292 Act: 34 Size: 1 MB 网页链接